EC Gynaecology

Introduction

Uterine fibroids (MM) is one of the most common gynecological diseases of non-inflammatory origin [15,22]. At the same time, the significance of the inflammatory process in the formation and growth of myomatous nodes (MU) is currently being actively studied [21]. However, it is obviously secondary.

1. Adamyan LV., et al. “Uterine fibroids: diagnosis, treatment and rehabilitation”. M (2015): 100.
2. Bezhenar VF., et al. “Innovative approaches to restoring reproductive function in patients with uterine myoma”. Obstetrics and Gynecology 1 (2016): 80-87.
3. Beck U., et al. “Obstetrics and gynecology: Per. from English”. M: GEOTAR MEDICINE (1997): 719.
4. Vikhlyaeva EM. “Guidelines for the diagnosis and treatment of uterine leiomyoma”. M: MED press-inform (2004): 400.
5. Kustarov VN., et al. “Myoma uterus”. SPb: SPbMAPO (2001): 32.
6. Linde VA., et al. “Uterine myoma and myomectomy”. M: "Sweet Group" (2010): 94.
7. Linde VA and Tatarova NA. “Endometriosis”. M: GEOTAR-Medicine (2010): 192.
8. Radzinsky VE and Fuchs AM. “Gynecology”. GEOTAR-Media (2016): 988.
9. Savitsky GA and Savitsky AG. “What is uterine fibroids?”. St. Petersburg: ELBI-SPb (2016): 216.
10. Tikhomirov AL., et al. “Etiology and pathogenesis of uterine leiomyoma - facts, hypotheses, reflections”. AG-info 3 (2006): 3-8.
11. Al Hendi SP., et al. The Journal of Clinical Endocrinology and Metabolism4 (2015): E572-E582.
12. Bulun SE., et al. “Uterine leiomyoma. Stem cells: Progestonic growth stimulation”. Reproductive Medicine5 (2015): 357-365.
13. Chabbert N., et al. “Myoma growth and medical options for treatment”. Fertility and Sterility3 (2014): 630-639.
14. Croce S., et al. The American Journal of Surgical Pathology10 (2014): 1330-1339.
15. Donnez J., et al. “Ulipristal acetate versus placebo for fibroid treatment before surgery”. The New England Journal of Medicine5 (2012): 409-420.
16. Jiang JF., et al. “Aberrant expressed long non-coding RNA in the eutopic endometrium of patients with myoma adenomyosis”. European Journal of Obstetrics and Gynecology and Reproductive Biology 199 (2016): 32-37.
17. Karmon AE., et al. “MicroRNAs in the development and pathobiology of uterine leiomyoma: is this evidence of support for future strategies for clinical intervention?” Human Reproduction Update5 (2014): 670-687.
18. Khan KN., et al. “Participation factor-induced epithelial-mesenchymal transition of human hepatocyte growth in adenomyosis”. Biology of Reproduction2 (2015): 35.
19. Leyendecker G., et al. “Adenomyosis and endometriosis. Re-examination of their association to obtain a more complete understanding of the mechanisms of automatic trauma”. Archives of Gynecology and Obstetrics 4 (2015): 917-932.
20. Mehine M., et al. Proceedings of the National Academy of Sciences of the United States of America5 (2016): 1315-1320.
21. Owen C and Armstrong AY. “Clinical Management of Leiomyoma”. Obstetrics and Gynecological Clinics1 (2015): 67-85.
22. Soliman AM., et al. “Direct and indirect costs for uterine fibroids: systematic review of literature between 2000 and 2013”. American Journal of Obstetrics and Gynecology2 (2015): 141-160.
23. Shutders I., et al. “Activation of MAPK / ERK Cell by a signal cascade in the uterine cells of smooth muscles of women with Adenomyosis”. Reproductive Sciences12 (2015): 1549-1560.
24. Struble J., et al. “Adenomyosis: Clinical Overview”. Journal of Minimally invasive Gynecology2 (2016): 164-185.
25. Yn R., et al. “American association of clinical endocrinologists and American college of endocrinology - clinical practice guidelines for developing a diabetes mellitus comprehensive care plan – 2015”. The Journal of Clinical Endocrinology and Metabolism4 (2015): 601-606.